Now let's talk about the new kid in town. Viking focuses on GIP/GLP-1 receptor agonists and has a candidate, VK2735, in late-stage clinical trials. As an injectable (like the Novo Nordisk and ...

Viking (VKTX) is in the midst of a phase 2a dosing trial of its oral obesity drug VK2735, with a data readout expected in the second half of the year. The company is expected to launch a phase 3 ...

The real Holy Grail is a weight-loss-in-a-pill formulation, which has investors very interested in Viking Therapeutics‘ (NASDAQ:VKTX) VK2735, which is showing better efficacy than Novo Nordisk ...

In contrast, Viking Therapeutics' shares experienced modest gains. Viking's VK2735, a dual GLP-1/GIP receptor agonist, is seen as potentially superior to Novo Nordisk's semaglutide, which only targets ...

Sure, the Viking bulls could point out that there’s more than just VK2735 in its pipeline, with exposure in NASH and X-ALD. However, all of these developments are pre-stage III, and thus ...

In contrast, Viking Therapeutics' shares experienced modest gains. Viking's VK2735, a dual GLP-1/GIP receptor agonist, is seen as potentially superior to Novo Nordisk's semaglutide, which only ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to take a look at where Viking Therapeutics, Inc. (NASDAQ:VKTX) stands ...

The recent data from Novo Nordisk’s Phase 3b trials highlighted the potential advantages of Viking’s VK2735. Pantginis emphasizes that VK2735, a dual GLP-1/GIP receptor agonist, may ...

On November 3, 2024, Viking released positive trial data for VK2735, the Company's anti-obesity drug, as part of a presentation at the Obesity Week medical meeting, causing Viking's stock price to ...

During the 1980s and 1990s, Ghanaian artists created vibrant hand-painted movie posters to promote Hollywood blockbuster films. These posters served as promotional material for mobile cinemas that ...

such as Viking’s dual GLP-1/GIP receptor agonist VK2735 and Structure Therapeutics' oral GLP-1 receptor agonist, GSBR-1290. Furthermore, despite a re-opening market for IPOs (initial public ...